Primary Site >> Biliary tract Cancer

Gene >> MAP2K7

  • 1997
  • 2003
  • 2004
  • 2006
  • 2007
  • 2008
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma cells treated with 5-azacytidine.
PMID: 9252136
 Ref: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
PMID: 12692057
Ref: Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma.
PMID: 12717393
 Ref: A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
PMID: 15743030
 Ref: Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.
PMID: 16950403
 Ref: Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells.
PMID: 17294242
 Ref: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
PMID: 18813828
 Ref: Molecular targeted therapy of biliary tract cancer--results of the first clinical studies.
PMID: 20388063
Ref: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
PMID: 20698202
Ref: Advances in the treatment of metastatic or unresectable biliary tract cancer.
PMID: 20943640
 Ref: Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2.
PMID: 21130731
Ref: Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
PMID: 21331764
 Ref: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
PMID: 22510747
 Ref: Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
PMID: 23091117
Ref: Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma.
PMID: 23254774
Ref: Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
PMID: 23315987
Ref: Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
PMID: 23391555
 Ref: A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done.
PMID: 24857099
Ref: Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
PMID: 25152244
Ref: Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
PMID: 25435907
 Ref: Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
PMID: 25966433
 Ref: A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.
PMID: 26614007
Ref: Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.
PMID: 26683364
Ref: Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.
PMID: 27084680
Ref: Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.
PMID: 28078132
 Ref: Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
PMID: 27811010
Ref: Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
PMID: 28212293
Ref: Signaling pathways as therapeutic targets in biliary tract cancer.
PMID: 28282502
Ref: Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
PMID: 28422736
Ref: Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.
PMID: 28480077
Ref: Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
PMID: 29024814
 Ref: Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.
PMID: 29348467
Ref: Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of beta-Catenin.
PMID: 29415992
Ref: Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling.
PMID: 29446253
Ref: MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner.
PMID: 30322054